VCEL Vericel Corporation
Vericel Corporation (VCEL) is expected to report earnings on October 29, 2026, before the market open. The consensus earnings estimate is $0.02 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -9.6% since its last earnings release on July 30, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Vericel Corporation
Vericel Corp is engaged in the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets two cell therapy products including Carticel and Epicel.
Sector
Healthcare
Industry
Biotechnology